Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%
Market cap
$3.6B
P/E
17.4×
Fwd P/E
5.2×
Dividend yield
0.58%
F-score
5/9
Altman Z
1.09
Beneish M
−2.68
Dividend safety
45/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
17.14 6.37 9.96 5.53

+8 more quarters

P/S ratio
0.58 0.25 0.30 0.44
P/FCF ratio
7.66 2.79 4.48 4.45
P/Operating CF
33.23 6.93 13.20 10.52
P/B ratio
3.53 1.73 2.47 3.06
EV/Sales
1.79 1.46 1.60 1.74
EV/EBITDA
7.78 6.33 6.92 7.07
EV/FCF
23.66 16.09 23.93 17.52
Current Ratio
1.95 1.97 1.82 1.75
Net Debt/EBITDA
18.06 23.59 30.45 19.51
Debt/Equity
8.50 9.49 11.49 9.74
Earnings Yield
5.83% 15.69% 10.04% 18.07%
Free Cash Flow Yield
13.05% 35.91% 22.30% 22.47%
Free Cash Flow per Share
0.12 0.72 0.37 0.57
Book value per Share
3.83 3.47 2.90 3.49
Free Cash Flow
31.00 188.00 96.00 149.00
EV/EBIT
13.32 10.91 12.05 9.09
Other line items

Show all line items

Columns are period end dates